Metagenomi Therapeutics, Inc.
MGX
$1.46
-$0.02-1.35%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -12.57% | -19.99% | -16.16% | -0.88% | -14.36% |
| Total Depreciation and Amortization | -1.66% | 6.43% | 11.77% | 18.39% | 28.52% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -32.23% | 63.83% | 81.68% | 353.48% | 2,594.21% |
| Change in Net Operating Assets | 62.97% | 35.57% | 11.06% | -57.72% | -125.77% |
| Cash from Operations | 18.50% | 11.38% | 3.46% | -1.80% | -19.32% |
| Capital Expenditure | 81.57% | 81.78% | 65.05% | 69.15% | 68.27% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 222.37% | 294.93% | 90.29% | 8.54% | -253.10% |
| Cash from Investing | 217.44% | 277.83% | 120.54% | 35.69% | -292.76% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.77% | -99.87% | -99.87% | -100.00% | -- |
| Repurchase of Common Stock | -- | -- | 75.79% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 59.60% | 89.15% | 97.65% | -- |
| Cash from Financing | -100.42% | -100.52% | -100.90% | -103.12% | 8,201.68% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 112.61% | 109.97% | -460.13% | -1,310.61% | -153.49% |